The networks also study treatments and preventions for other infectious diseases and were instrumental in testing the Covid vaccine.
Category: National Institutes of Health
-
H.I.V. Research Networks Face Uncertain Future Amid Funding Delays
The New York Times – Business: -
Trump Backtracks on Plan for New Controls on N.I.H. Grants
The New York Times – Business:Democrats and Republicans in Congress opposed the creation of a commission with the power to veto federal research awards.
-
Has Your Scientific Work Been Cut? We Want to Hear.
For a new series, Times journalists are speaking with scientists whose research has ended as a result of policy changes by the Trump administration.
-
Study Undercuts Idea That Cash Payments to Poor Families Help Child Development
Rigorous new research appears to show that monthly checks intended to help disadvantaged children did little for their well-being, adding a new element to a dispute over expanded government aid.
-
Kennedy Says ‘Charlatans’ Are No Reason to Block Unproven Stem Cell Treatments
The U.S. health secretary said people should have access to experimental therapies including unregulated stem cells. But some methods have resulted in blindness, tumors and other injuries.
-
Top N.I.H. Official Abruptly Resigns as Trump Orders Deep Cuts
Dr. Lawrence Tabak, the No. 2 official at the National Institutes of Health, did not give a reason for his departure.
-
Republicans Love Trump’s Spending Cuts. Just Not in Their States.
Even as they praise the president’s unilateral actions to slash federal spending, G.O.P. lawmakers have quietly moved to seek carve outs or exemptions for their own constituents.
-
Five Ways R.F.K. Jr. Could Undermine Lifesaving Childhood Vaccines
If he is confirmed as H.H.S. secretary, the longtime vaccine critic would be in a position to change the government’s immunization recommendations and delay the development of new vaccines.
-
Embattled Alzheimer’s Researcher Is Charged With Fraud
Hoau-Yan Wang, a professor at City College, published studies supporting simufilam, now in advanced clinical trials.
